Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects

Published:2018-07-20 Issue:12 Volume:58 Page:1578-1585
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Krishna Rajesh¹,Gheyas Ferdous¹,Corr Christy¹²,Cote Josee¹,Liu Yang¹,Wagner John¹³,Gutstein David E.¹⁴

Affiliation:

1. MRL, Merck & Co, Inc; Kenilworth NJ USA

2. BCH Research Solutions; LLC; West Chester PA USA

3. Takeda Pharmaceuticals International Co; Cambridge MA USA

4. Janssen Research & Development; LLC; Raritan NJ USA

Funder

Merck

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.1287/fullpdf

Reference23 articles.

1. Effect of anacetrapib on atheroschlerotic vascular disease;Bowman;N Engl J Med,2017

2. Merck & Co. Inc, press release: Merck provides update on anacetrapib development program. http://investors.merck.com/news/press-release-details/2017/Merck-Provides-Update-on-Anacetrapib-Development-Program/default.aspx 2018

3. Biochemical characterization of cholesteryl ester transfer protein inhibitors;Ranalletta;J Lipid Res,2010

4. O'Neil E Sparrow CP Chen Y Identification and characterization of anacetrapib (MK-0859): a novel CETP inhibitor.Presented at: XVI International Symposium on Drugs Affecting Lipid Metabolism . New York, 4-7 October 2007

5. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects;Krishna;Br J Clin Pharmacol,2009

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects;Advances in Therapy;2021-06-08